Get the Stockscreener App
6.05
5.17%
-0.33
Abeona Therapeutics Inc stock is traded at $6.05, with a volume of 1.17M.
It is down -5.17% in the last 24 hours and up +7.65% over the past month.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
See More
Previous Close:
$6.38
Open:
$6.39
24h Volume:
1.17M
Relative Volume:
0.97
Market Cap:
$344.82M
Revenue:
$5.82M
Net Income/Loss:
$71.18M
P/E Ratio:
6.067
EPS:
0.9972
Net Cash Flow:
$-84.30M
1W Performance:
-13.57%
1M Performance:
+7.65%
6M Performance:
+17.25%
1Y Performance:
-9.02%
1-Day Range:
$6.03
$6.39
1-Week Range:
$6.03
$7.0683
52-Week Range:
$4.00
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
6.05 | 344.82M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Precision Trading with Abeona Therapeutics Inc. (ABEO) Risk Zones - Stock Traders Daily
Abeona Therapeutics (ABEO) CFO has shares withheld to cover taxes - Stock Titan
Abeona Therapeutics Inc (PCJ) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Abeona Therapeutics (ABEO) Expands Zevaskyn Access with New Trea - GuruFocus
July 2026's Leading Growth Companies With Insider Ownership - simplywall.st
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN® - The Manila Times
Cincinnati Children’s activated for rare wound gene therapy - Stock Titan
Daily Brief Health Care: JPJ (TCM) Limited(TCM), Abeona Therapeutics , Mani Inc, BioVie , Propanc Biopharma, Tivic Health Systems Inc and more - Smartkarma
Abeona Therapeutics (ABEO) Surges 3.26%: Key Levels and Potential Breakout ZoneDaily Profile - dars.gov.et
Abeona Therapeutics (NASDAQ: ABEO) shifts 760,870 warrants to SILV Fund - Stock Titan
Form 4 Abeona Therapeutics Inc For: 9 July By Investing.com - Investing.com UK
Brendan O’Malley sells $83,912 in Abeona Therapeutics stock By Investing.com - Investing.com Australia
Abeona Therapeutics CEO Seshadri Vishwas sells $473k in stock By Investing.com - Investing.com Nigeria
Abeona Therapeutics CCO Vasanthavada Madhav sells $87,784 in stock By Investing.com - Investing.com Nigeria
Abeona Therapeutics CCO Vasanthavada Madhav sells $87,784 in stock - Investing.com UK
Abeona Therapeutics CEO Seshadri Vishwas sells $473k in stock - Investing.com
Brendan O’Malley sells $83,912 in Abeona Therapeutics stock - Investing.com India
Abeona (ABEO) CFO sells 24,880 shares to cover taxes on vested stock - Stock Titan
Tax-related stock sale by Abeona (ABEO) CEO leaves 1.31M shares - Stock Titan
Abeona Therapeutics (ABEO) SVP sells shares to cover tax obligations - Stock Titan
Abeona Therapeutics (ABEO) CCO sells 12,606 shares, retains 290,623 - Stock Titan
Form 144 ABEONA THERAPEUTICS INC. For: 9 July By Investing.com - Investing.com South Africa
ABEO (NASDAQ) Form 144 shows 141,333 restricted shares planned for sale - Stock Titan
ABEO (ABEO) investor plans to sell 12,606 shares after equity award - Stock Titan
ABEO (NASDAQ: ABEO) director reports proposed stock sales in Form 144 - Stock Titan
ABEO (Nasdaq: ABEO) files Form 144: 34,230 restricted shares; insider sales noted - Stock Titan
ABEO Q1 2026 Earnings: Narrowed Loss Surpasses Expectations as Stock Gains 3.82%Earnings Expansion Phase - dars.gov.et
ABEO (NASDAQ: ABEO) Rule 144 sale notice — 18,160 shares - Stock Titan
Abeona Therapeutics names Keith Goldan to board of directors - Investing.com
Price to sales forward of Abeona Therapeutics Inc. – NASDAQ:ABEO - TradingView
uniQure, Protara, Abeona, Cerebras, Verisign Insider Shake-Up - TipRanks
Insider Sell Alert: Leila Alland Sells Shares of Abeona Therapeu - GuruFocus
Abeona Therapeutics (ABEO) director Alland Leila sells 11,000 shares - Stock Titan
ABEOAbeona Therapeutics Inc Latest SEC Filings - Finviz
Technical Reactions to ABEO Trends in Macro Strategies - Stock Traders Daily
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Abeona Therapeutics Inc.(NasdaqCM: ABEO) added to Russell 2000 Value-Defensive Index - marketscreener.com
Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Enterprise value to revenue forward of Abeona Therapeutics Inc. – NASDAQ:ABEO - TradingView
Price to earnings forward of Abeona Therapeutics Inc. – NASDAQ:ABEO - TradingView
Price to sales forward of Abeona Therapeutics, Inc. – HAM:PCJ - TradingView
ABEO Should I Buy - Intellectia AI
Enterprise value to EBITDA forward of Abeona Therapeutics Inc. – NASDAQ:ABEO - TradingView
Price to earnings forward of Abeona Therapeutics, Inc. – HAM:PCJ - TradingView
Enterprise value to EBIT forward of Abeona Therapeutics Inc. – NASDAQ:ABEO - TradingView
Price to book forward of Abeona Therapeutics Inc. – NASDAQ:ABEO - TradingView
Top Growth Companies With Strong Insider Ownership For June 2026 - simplywall.st
Trading the Move, Not the Narrative: (ABEO) Edition - Stock Traders Daily
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abeona Therapeutics Inc Stock (ABEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vazzano Joseph Walter | Chief Financial Officer |
Jul 09 '26 |
Sale |
6.96 |
24,880 |
173,257 |
493,557 |
| Seshadri Vishwas | Chief Executive Officer |
Jul 09 '26 |
Sale |
6.96 |
67,971 |
473,330 |
1,306,108 |
| O'Malley Brendan M. | SVP, Chief Legal Officer |
Jul 09 '26 |
Sale |
6.96 |
12,050 |
83,913 |
427,953 |
| Vasanthavada Madhav | Chief Commercial Officer |
Jul 09 '26 |
Sale |
6.96 |
12,606 |
87,784 |
290,623 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):